British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

R. Hamish Mcallister-Williams, David S. Baldwin, Roch Cantwell, Abby Easter, Eilish Gilvarry, Vivette Glover, Lucian Green, Alain Gregoire, Louise M. Howard, Ian Jones, Hind Khalifeh, Anne Lingford-Hughes, Elizabeth McDonald, Nadia Micali, Carmine M. Pariante, Lesley Peters, Ann Roberts, Natalie C. Smith, David Taylor, Angelika WieckLaura M. Yates, Allan H. Young

Research output: Contribution to journalArticlepeer-review

145 Scopus citations

Abstract

Decisions about the use of psychotropic medication in pregnancy are an ongoing challenge for clinicians and women with mental health problems, owing to the uncertainties around risks of the illness itself to mother and fetus/infant, effectiveness of medications in pregnancy and risks to the fetus/infant from in utero exposure or via breast milk. These consensus guidelines aim to provide pragmatic advice regarding these issues. They are divided into sections on risks of untreated illness in pregnancy; general principles of using drugs in the perinatal period; benefits and harms associated with individual drugs; and recommendations for the management of specific disorders.

Original languageEnglish
Pages (from-to)519-552
Number of pages34
JournalJournal of Psychopharmacology
Volume31
Issue number5
DOIs
StatePublished - 1 May 2017
Externally publishedYes

Keywords

  • Antidepressants
  • antipsychotics
  • anxiolytics
  • birth defects
  • breastfeeding
  • child development
  • conception
  • fertility
  • hypnotics
  • mood stabilisers
  • neonatal problems
  • postpartum
  • pregnancy
  • pregnancy outcome
  • psychiatric illness
  • psychotropics
  • teratogenicity

Fingerprint

Dive into the research topics of 'British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017'. Together they form a unique fingerprint.

Cite this